Screening for latent tuberculosis infection: Performance of tuberculin skin test and interferon-γ release assays under real-life conditions

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1791-1795

  Kleinert, Stefan ^a   Tony, H P ^a   Krueger, K ^b   Detert, J ^c   Mielke, F ^d   Rockwitz, K ^e   Schwenke, R ^f   Burmester, G R ^c   Diel, R ^g   Feuchtenberger, M ^a   Kneitz, C ^h  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Praxiszentrum St Bonifatius   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Gemeinschaftspraxis Innere Medizin   (Germany)

^e Schwerpunktpraxis Innere Medizin/Rheumatologie/Osteologie   (Germany)

^f Schwerpunktpraxis Innere Medizin/Rheumatologie/ Osteologie   (Germany)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h Klinik für Innere Medizin II   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BCG VACCINATION; FEMALE; HUMAN; HUMAN CELL; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATIC DISEASE; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR; THORAX RADIOGRAPHY; TUBERCULIN TEST;

FEMALE; HUMANS; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MASS SCREENING; MIDDLE AGED; PROFESSIONAL PRACTICE; PROSPECTIVE STUDIES; RECURRENCE; TUBERCULIN TEST;

EID: 84867403451     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200941     Document Type: Article

References (12)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
2. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
3. Gómez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61.
4. Diel R, Loddenkemper R, Meywald-Walter K, et al. Comparative performance of tuberculin skin test, QuantiFERON-TB-Gold In Tube assay, and T-Spot.TB test in contact investigations for tuberculosis. Chest 2009;135:1010-8.
5. Diel R, Hauer B, Loddenkemper R, et al. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases]. Z Rheumatol 2009;68:411-6.
6. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
7. Smith R, Cattamanchi A, Steingart KR, et al. Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 2011;23:377-84.
8. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59:1-25.
9. Kleinert S, Kurzai O, Elias J, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2010;69:782-4.
10. Schablon A, Beckmann G, Harling M, et al. Prevalence of latent tuberculosis infection among health care workers in a hospital for pulmonary diseases. J Occup Med Toxicol 2009;4:1.
11. Matulis G, Jüni P, Villiger PM, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
12. Hsia EC, Schluger N, Cush J, et al. Interferon-gamma release assay versus tuberculin skin test across RA, PsA, and AS patients prior to treatment with golimumab, a human anti-TNF antibody. Arthritis Rheum 2012 2012 Jan 11. doi: 10.1002/art.34382. [Epub ahead of print]